168 related articles for article (PubMed ID: 18971540)
1. In vivo imaging of renal redox status during azelnidipine treatment.
Hirayama A; Ueda A; Oteki T; Nagase S; Aoyagi K; Koyama A
Hypertens Res; 2008 Aug; 31(8):1643-50. PubMed ID: 18971540
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of oxidative stress in ischemia-reperfusion renal injury using electron paramagnetic resonance.
Hirayama A; Nagase S; Ueda A; Oteki T; Takada K; Obara M; Inoue M; Yoh K; Hirayama K; Koyama A
Am J Physiol Renal Physiol; 2005 Mar; 288(3):F597-603. PubMed ID: 15536173
[TBL] [Abstract][Full Text] [Related]
3. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K
J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
[TBL] [Abstract][Full Text] [Related]
4. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K
Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110
[TBL] [Abstract][Full Text] [Related]
5. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S
Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
Shokoji T; Fujisawa Y; Kiyomoto H; Rahman M; Sun GP; Fan YY; Kimura S; Kohno M; Abe Y; Nishiyama A
Hypertens Res; 2005 Dec; 28(12):1017-23. PubMed ID: 16671342
[TBL] [Abstract][Full Text] [Related]
7. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
[TBL] [Abstract][Full Text] [Related]
8. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
[TBL] [Abstract][Full Text] [Related]
9. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
[TBL] [Abstract][Full Text] [Related]
11. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Nagasu H; Satoh M; Fujimoto S; Tomita N; Sasaki T; Kashihara N
Hypertens Res; 2012 Mar; 35(3):348-55. PubMed ID: 22072106
[TBL] [Abstract][Full Text] [Related]
12. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
Nakano K; Egashira K; Tada H; Kohjimoto Y; Hirouchi Y; Kitajima S; Endo Y; Li XH; Sunagawa K
J Hypertens; 2006 Sep; 24(9):1881-9. PubMed ID: 16915039
[TBL] [Abstract][Full Text] [Related]
13. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
Fujisawa M; Yorikane R; Chiba S; Koike H
J Cardiovasc Pharmacol; 2009 Apr; 53(4):325-32. PubMed ID: 19295444
[TBL] [Abstract][Full Text] [Related]
14. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
[TBL] [Abstract][Full Text] [Related]
15. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
[TBL] [Abstract][Full Text] [Related]
16. Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.
Yamada J; Tomiyama H; Matsumoto C; Yoshida M; Shiina K; Yamashina A
J Cardiol; 2008 Apr; 51(2):114-20. PubMed ID: 18522784
[TBL] [Abstract][Full Text] [Related]
17. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Fukuda T; Numao T; Shimada K; Kario K
J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
[TBL] [Abstract][Full Text] [Related]
18. Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.
Takano Y; Ueyama T; Ishikura F
J Cardiol; 2012 Jul; 60(1):18-22. PubMed ID: 22436293
[TBL] [Abstract][Full Text] [Related]
19. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.
Manabe S; Okura T; Fukuoka T; Higaki J
Eur J Pharmacol; 2007 Jul; 567(3):252-7. PubMed ID: 17544393
[TBL] [Abstract][Full Text] [Related]
20. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
Kurobe H; Matsuoka Y; Hirata Y; Sugasawa N; Maxfield MW; Sata M; Kitagawa T
J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1501-8. PubMed ID: 23535154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
